EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Co‐Delivery of Varicella Zoster Virus gE and gI Dual‐Antigen mRNA Vaccine With CpG‐ODN Elicits Robust Immunity

Lingyan Cui, Sibo Zhang, Wenhui Xue, Hongjing Liu, Hong Wang, Hai Li, Yarong Zeng, Huizheng Zhang, Yaohan Li, Minqing Hong, Lin Chen, Jun Zhang und 4 weitere

MedComm · 2026-11 · 7 (11)

DOI: 10.1002/mco2.71117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm, online erschienen am 01.11.2026. Verfasst von Lingyan Cui und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, School of Life Sciences, Xiamen U…. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herpes zoster (HZ), caused by reactivation of latent varicella zoster virus (VZV), remains a growing health burden. Developing new HZ vaccines with high efficacy and improved tolerability could address limitations of current vaccines and increase vaccination uptake and completion rates. To identify an optimal antigen design, we systematically evaluated multiple mRNA candidates based on VZV glycoprotein E (gE) and I (gI). In mice, membrane‐localized gE induced the strongest and most durable antibody responses, whereas inclusion of gI markedly enhanced T‐cell responses. Co‐delivery of membrane‐localized gE and gI (gE+gI Lmix) elicited the most robust cellular responses, outperforming both single‐antigen and fusion constructs. We therefore selected gE+gI Lmix for further optimization with CpG oligodeoxynucleotide (CpG‐ODN) adjuvants. In both naïve and VZV‐primed mice, CpG‐ODN 1018 increased neutralizing antibody titers and significantly enhanced antigen‐specific CD4 + and CD8 + IFN‐γ + T‐cell responses, with a Th1‐biased profile. The resulting humoral and cellular responses matched or exceeded those induced by Shingrix in mice. Safety assessments revealed no distinct systemic toxicity or histopathological abnormalities following CpG‐ODN 1018 administration. Together, these findings identify dual‐antigen gE/gI mRNA vaccination, particularly in combination with CpG‐ODN 1018, as a promising strategy for HZ prevention, with enhanced cellular immunogenicity and an acceptable preclinical safety profile.

Schlagwörter

Stichwörter der Autor:innen

CpG‐ODN 1018glycoprotein E/glycoprotein Iherpes zostermRNA vaccinevaricella zoster virus

Autor:innen und Institutionen

  • State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, School of Life Sciences, Xiamen University Xiamen China.
  • National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, National Innovation Platform for Industry-Education Integration in Vaccine Research…

Förderung

  • National Key Research and Development Program of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Cui, L., Zhang, S., Xue, W., Liu, H., Wang, H., Li, H., Zeng, Y., Zhang, H., Li, Y., Hong, M., Chen, L., Zhang, J., Gu, Y., Li, S., Li, T., & Xia, N. (2026). Co‐Delivery of Varicella Zoster Virus gE and gI Dual‐Antigen mRNA Vaccine With CpG‐ODN Elicits Robust Immunity. MedComm, 7(11). https://doi.org/10.1002/mco2.71117

Vancouver

Cui L, Zhang S, Xue W, Liu H, Wang H, Li H, et al. Co‐Delivery of Varicella Zoster Virus gE and gI Dual‐Antigen mRNA Vaccine With CpG‐ODN Elicits Robust Immunity. MedComm. 2026;7(11). doi:10.1002/mco2.71117

BibTeX
@article{Cui2026,
  author = {Cui, Lingyan and Zhang, Sibo and Xue, Wenhui and Liu, Hongjing and Wang, Hong and Li, Hai and Zeng, Yarong and Zhang, Huizheng and Li, Yaohan and Hong, Minqing and Chen, Lin and Zhang, Jun and Gu, Ying and Li, Shaowei and Li, Tingting and Xia, Ningshao},
  title = {Co‐Delivery of Varicella Zoster Virus gE and gI Dual‐Antigen mRNA Vaccine With CpG‐ODN Elicits Robust Immunity},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {11},
  doi = {10.1002/mco2.71117}
}
Kostenlos starten →